Keyphrases
Chronic Lymphocytic Leukemia
100%
Clinical Treatment
100%
Clinical Heterogeneity
100%
Tumor
33%
Minimal Residual Disease
22%
ATR Inhibition
22%
Short Telomere
11%
Tumor Protein p53 (TP53)
11%
Chemotherapy
11%
Therapeutic Target
11%
Prognostic Potential
11%
Prognostic Marker
11%
Prognostic Factors
11%
Treatment Type
11%
Therapeutic Strategies
11%
Potential Therapeutics
11%
Selective Cytotoxicity
11%
Therapeutic Goals
11%
CD49d
11%
Anergy
11%
Unresponsiveness
11%
10-year Survival
11%
Adverse Cytogenetics
11%
Disease Heterogeneity
11%
IGHV Genes
11%
Biological Insight
11%
Treatment Line
11%
Synthetic Lethality
11%
ATR Inhibitor
11%
Ibrutinib
11%
Therapeutic Insights
11%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Neoplasm
33%
Minimal Residual Disease
22%
In Vitro
11%
Prognostic Factor
11%
Cytotoxicity
11%
Immunoglobulin M
11%
Immunoglobulin D
11%
Lethality
11%
Telomere
11%
IGHV@
11%
Ibrutinib
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Neoplasm
33%
Minimal Residual Disease
22%
Chemotherapy
11%
Cytotoxicity
11%
Immunoglobulin M
11%
Lethality
11%
Ibrutinib
11%
Immunoglobulin D
11%
Diseases
11%